Podcasts about CRS

Send us a textDo you have CRS like we do?We might have gotten heat stroke, but you still got your episode! Daniel forgets Dr. Jones and Marcus can't remember anything. Wear protective clothing to protect you from the sun's harmful rays. Support the show

In a conversation with CancerNetwork®, Benjamin Golas, MD, spoke about the current treatment landscape for patients with peritoneal carcinomatosis, discussing how the use of pressurized intraperitoneal aerosolized chemotherapy (PIPAC) may offer improvements in clinical outcomes. Golas is the chief of Surgical Oncology of the Central Region for Hackensack Meridian Health. According to Golas, standard therapeutic approaches include combining cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), which may cause collateral damage to healthy tissue while eliciting toxicities such as nausea, vomiting, and bone marrow suppression. Additionally, certain surgical procedures may last up to 14 hours and confer an extensive morbidity profile, thereby increasing complication rates. Golas described how PIPAC, a minimally invasive laparoscopic technique, may help avoid pain and other adverse effects associated with surgery while facilitating more direct delivery of chemotherapy in the peritoneal cavity. He noted that treatment with PIPAC typically takes 45 minutes to an hour, allowing some patients to return home on the same day of the procedure.  Although clinicians are still learning the correct indications for PIPAC, Golas stated that any patient with peritoneal carcinomatosis should be a candidate to receive treatment with this strategy. Furthermore, he described how the next steps for improving outcomes in this population include finding new ways to incorporate PIPAC into more extensive treatment plans for patients.  “PIPAC is a new treatment and a new potential option that doesn't replace systemic chemotherapy, but I do think it can work in conjunction with systemic chemotherapy. We can offer this bimodal approach where we're directly treating the peritoneal disease and offering [intravenous] chemotherapy,” Golas stated. “We clearly have a long way to go in terms of clinical trials and learning what the best ways are to use this. But there are patients out there who will benefit from that, so I think referral to a center that focuses and has expertise in PIPAC for patients with peritoneal carcinomatosis is critical.”

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss important advances in the treatment of prostate, bladder, and kidney cancers that were presented at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute and editor-in-chief of the ASCO Daily News.  I am delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of the GU Center at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that were presented at the 2025 ASCO Annual Meeting.  Our full disclosures are available in the transcript of this episode.  Jeanny, it is great to have you on the podcast. Dr. Jeanny Aragon-Ching: Oh, thank you so much, Neeraj. Dr. Neeraj Agarwal: Jeanny, let's begin with some prostate cancer abstracts. Let's begin with Abstract 5017 titled, “Phase 1 study results of JNJ-78278343 (pasritamig) in metastatic castration-resistant prostate cancer.” Can you walk us through the design and the key findings of this first-in-human trial? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this study, presented by Dr. Capucine Baldini, introduces pasritamig, a first-in-class T-cell redirecting bispecific antibody that simultaneously binds KLK2 on prostate cancer cells and CD3 receptor complexes on T cells. KLK2 is also known as human kallikrein 2, which is selectively expressed in prostate tissue. And for reference, KLK3 is what we now know as the PSA, prostate-specific antigen, therefore making it an attractive and specific target for therapeutic engagement. Now, while this was an early, first-in-human, phase 1 study, it enrolled 174 heavily pretreated metastatic CRPC patients. So many were previously treated with ARPIs, taxanes, and radioligand therapy. So given the phase 1 nature of this study, the primary objective was to determine the safety and the RP2D, which is the recommended phase 2 dose. Secondary objectives included preliminary assessment of antitumor activity. So, pasritamig was generally well tolerated. There were no treatment-related deaths. Serious adverse events were rare. And in the RP2D safety cohort, where patients received the step-up dosing up to 300 mg of IV every 6 weeks, the most common treatment-related adverse events were low-grade infusion reactions. There was fatigue and grade 1 cytokine release syndrome, what we call CRS. And no cases of neurotoxicity, or what we call ICANS, the immune effector cell-associated neurotoxicity syndrome, reported. Importantly, the CRS occurred in just about 8.9% of patients. All were grade 1. No patients required tocilizumab or discontinued treatment due to adverse events. So, this suggests a favorable safety profile, allowing hopefully for outpatient administration without hospitalization, which will be very important when we're thinking about bispecifics moving forward. In terms of efficacy, pasritamig showed promising activity. About 42.4% of evaluable patients achieved a PSA50 response. Radiographic PFS was about 6.8 months. And among patients with measurable disease, the objective response rate was about 16.1% in those with lymph node or bone metastases, and about 3.7% in those with visceral disease, with a median duration of response of about 11.3 months. So, altogether, this data suggests that pasritamig may offer a well-tolerated and active new potential option for patients with metastatic CRPC.   Again, as a reminder, with the caveat that this is still an early phase 1 study. Dr. Neeraj Agarwal: Thank you, Jeanny. These are promising results for a bispecific T-cell engager, pasritamig, in prostate cancer. I agree, the safety and durability observed here stand out, and this opens the door for further development, possibly even in earlier disease settings.  So, shifting now from immunotherapy to the evolving role of genomics in prostate cancer. So let's discuss Abstract 5094, a real-world, retrospective analysis exploring the prognostic impact of homologous recombination repair gene mutations, especially BRCA1 and BRCA2 mutations, in metastatic hormone-sensitive prostate cancer. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So this study was presented by Dr. David Olmos, represents one of the largest real-world analyses we have evaluating the impact of homologous recombination repair, or what we would call HRR, alterations in metastatic hormone-sensitive prostate cancer. So, this cohort included 556 men who underwent paired germline and somatic testing. Now, about 30% of patients had HRR alterations, with about 12% harboring BRCA1 or BRCA2 mutations and 16% having alterations in other HRR genes. Importantly, patients were stratified via CHAARTED disease volume, and outcomes were examined across treatment approaches, including ADT alone, doublet therapy, and triplet therapy. The prevalence of BRCA and HRR alterations were about similar between the metastatic hormone-sensitive prostate cancer and the metastatic castrate-resistant prostate cancer, with no differences observed, actually, between the patients with high volume versus low volume disease.  So, the key finding was that BRCA and HRR alterations were associated with poor clinical outcomes in metastatic hormone-sensitive prostate cancer. And notably, the impact of these alterations may actually be even greater in metastatic hormone-sensitive prostate cancer than previously reported in metastatic CRPC. So, the data showed that when BRCA mutations are present, the impact of the volume of disease is actually limited. So, poor outcomes were observed across the board for both high-volume and low-volume groups. So, the analysis showed that patients with HRR alterations had significantly worse outcomes compared to patients without HRR alterations. Median radiographic progression-free survival was about 20.5 months for the HRR-altered patients versus 30.6 months for the non-HRR patients, with a hazard ratio of 1.6. Median overall survival was 39 months for HRR-altered patients compared to 55.7 months for the non-HRR patients, with a hazard ratio of 1.5. Similar significant differences were observed when BRCA-mutant patients were compared with patients harboring non-BRCA HRR mutations. Overall, poor outcomes were independent of treatment of ARPI or taxanes. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data reinforce homologous recombination repair mutations as both a predictive and prognostic biomarker, not only in the mCRPC, but also in the metastatic hormone-sensitive setting as well. It also makes a strong case for incorporating genomic testing early in the disease course and not waiting until our patients have castration-resistant disease. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. And I think this really brings home the point and the lead up to the AMPLITUDE trial, which is LBA5006, a phase 3 trial that builds on this very concept of testing with a PARP inhibitor, niraparib, in the hormone-sensitive space. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the AMPLITUDE trial, a phase 3 trial presented by Dr. Gerhardt Attard, enrolled 696 patients with metastatic hormone-sensitive prostate cancer and HRR gene alterations. 56% of these patients had BRCA1 and BRCA2 mutations. Patients were randomized to receive abiraterone with or without niraparib, a PARP inhibitor. The majority of patients, 78% of these patients, had high-volume metastatic hormone-sensitive prostate cancer, and 87% of these patients had de novo metastatic HSPC. And 16% of these patients received prior docetaxel, which was allowed in the clinical trial. So, with a median follow-up of nearly 31 months, radiographic progression-free survival was significantly prolonged with the niraparib plus abiraterone combination, and median was not reached in this arm, compared to abiraterone alone, which was 29.5 months, with a hazard ratio of 0.63, translating to a 37% reduction in risk of progression or death. This benefit was even more pronounced in the BRCA1 and BRCA2 subgroup, with a 48% reduction in risk of progression, with a hazard ratio of 0.52. Time to symptomatic progression also improved significantly across all patients, including patients with BRCA1, BRCA2, and HRR mutations. Although overall survival data remain immature, early trends favored the niraparib plus abiraterone combination. The safety profile was consistent with prior PARP inhibitor studies, with grade 3 or higher anemia and hypertension were more common but manageable. Treatment discontinuation due to adverse events remained low at 11%, suggesting that timely dose modifications when our patients experience grade 3 side effects may allow our patients to continue treatment without discontinuation. These findings support niraparib plus abiraterone as a potential new standard of care in our patients with metastatic hormone-sensitive prostate cancer with HRR alterations, and especially in those who had BRCA1 and BRCA2 mutations. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. This trial is especially exciting because it brings PARP inhibitors earlier into the treatment paradigm. Dr. Neeraj Agarwal: Exactly. And it is exciting to see the effect of PARP inhibitors in the earlier setting.  So Jeanny, now let's switch gears a bit to bladder cancer, which also saw several impactful studies. Could you tell us about Abstract 4502, an exploratory analysis from the EV-302 trial, which led to approval of enfortumab vedotin plus pembrolizumab for our patients with newly diagnosed metastatic bladder cancer? So here, the authors looked at the outcomes in patients who achieved a confirmed complete response with EV plus pembrolizumab. Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, EV-302 demonstrated significant improvements in progression-free and overall survival for patients previously treated locally advanced or metastatic urothelial cancer, I'll just call it metastatic UC, as a frontline strategy, establishing EV, which is enfortumab vedotin, plus pembro, with pembrolizumab as standard of care in this setting.  So, this year at ASCO, Dr Shilpa Gupta presented this exploratory responder analysis from the phase 3 EV-302 trial. Among 886 randomized patients, about 30.4% of patients, this is about 133, in the EV+P arm, and 14.5% of the patients in the chemotherapy arm, achieved a confirmed complete response. They call it the CCR rates. So for patients who achieved this, median PFS was not reached with EV+P compared to 26.9 months with chemotherapy, with a hazard ratio of 0.36, translating to a 64% reduction in the risk of progression. Overall survival was also improved. So the median OS was not reached in either arm, but the hazard ratio favored the EV+P at 0.37, translating to a 63% reduction in the risk of death. The median duration of complete response was not reached with EV+P compared to 15.2 months with chemotherapy. And among those patients who had confirmed CRs at 24 months, 78% of patients with the EV+P arm remained progression-free, and around 95% of the patients were alive, compared to 54% of patients who were progression-free and 86% alive of the patients in the chemotherapy arm. Safety among responders were also consistent with prior reports. Grade 3 or higher treatment-related adverse events occurred in 62% of EV+P responders and 72% of chemotherapy responders. Most adverse events were managed with dose modifications, and importantly, no treatment-related deaths were reported among those who were able to achieve complete response.  So these findings further reinforce EV and pembro as the preferred first-line therapy for metastatic urothelial carcinoma, offering a higher likelihood of deep, durable responses with a fairly manageable safety profile. Dr. Neeraj Agarwal: Thank you for the great summary, Jeanny. These findings underscore the depth and durability of responses achievable with this combination and also suggest that achieving a response may be a surrogate for long-term benefit in patients with metastatic urothelial carcinoma.  So now, let's move to Abstract 4503, an exploratory ctDNA analysis from the NIAGARA trial, which evaluated perioperative durvalumab, an immune checkpoint inhibitor, in muscle-invasive bladder cancer. So what can you tell us about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in NIAGARA, presented by Dr. Tom Powles, the addition of perioperative durvalumab to neoadjuvant chemotherapy, gem/cis, significantly improved event-free survival, overall survival, and pathologic complete response in patients with cisplatin-eligible muscle-invasive bladder cancer. Recall that this led to the U.S. FDA approval of this treatment regimen on March 28, 2025.  So, a planned exploratory analysis evaluated the ctDNA dynamics and their association with clinical outcomes, which was the one presented recently at ASCO. So, the study found that the incidence of finding ctDNA positivity in these patients was about 57%. Following neoadjuvant treatment, this dropped to about 22%, with ctDNA clearance being more common in the durvalumab arm, about 41%, compared to the chemotherapy control arm of 31%. Notably, 97% of patients who remained ctDNA positive prior to surgery failed to achieve a pathologic CR. So, this indicates a strong association between ctDNA persistence and lack of tumor eradication. So, postoperatively, only about 9% of patients were ctDNA positive. So, importantly, durvalumab conferred an event-free survival benefit regardless of ctDNA status at both baseline and post-surgery. Among patients who were ctDNA positive at baseline, durvalumab led to a hazard ratio of 0.73 for EFS. So, this translates to a 27% reduction in the risk of disease recurrence, progression, or death compared to the control arm. In the post-surgical ctDNA-positive group, the disease-free survival was also improved with a hazard ratio of 0.49, translating to a 51% reduction in the risk of recurrence.  So, these findings underscore the prognostic value of ctDNA and suggest that durvalumab provides clinical benefit irrespective of molecular residual disease status. So, the data also supports that ctDNA is a promising biomarker for future personalized strategies in the perioperative treatment of muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Thank you, Jeanny. It is great to see that durvalumab is improving outcomes in these patients regardless of ctDNA status. However, based on these data, presence of ctDNA in our patients warrants a closer follow-up with imaging studies, because these patients with positive ctDNA seem to have a higher risk of recurrence. Dr. Jeanny Aragon-Ching: I agree, Neeraj.  Let's round out the bladder cancer discussion with Abstract 4518, which reported the interim results of SURE-02, which is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Can you tell us more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure, Jeanny. So, Dr Andrea Necchi presented interim results from the SURE-02 trial. This is a phase 2 study evaluating neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by a response-adapted bladder-sparing treatment and adjuvant pembrolizumab in patients with muscle-invasive bladder cancer.  So, in this interim analysis, 40 patients were treated and 31 patients were evaluable for efficacy. So, the clinical complete response rate was 38.7%. All patients achieving clinical complete response underwent bladder-sparing approach with a repeat TURBT instead of radical cystectomy. Additionally, 51.6% of patients achieved excellent pathologic response with a T stage of 1 or less after neoadjuvant therapy. The treatment was well tolerated, with only 12.9% of patients experiencing grade 3 or higher adverse events without needing dose reduction of sacituzumab. Molecular profiling, interestingly, showed that clinical complete response correlated with luminal and genomically unstable subtypes, while high stromal gene expression was associated with lack of response.  These results suggest that sacituzumab plus pembrolizumab combination has promising activity in this setting, and tolerability, and along with other factors may potentially allow a bladder preservation approach in a substantial number of patients down the line. Dr. Jeanny Aragon-Ching: Yeah, agree with you, Neeraj. And the findings are very provocative and support completing the full trial enrollment and further exploration of this strategy in muscle-invasive bladder cancer in order to improve and provide further bladder-sparing strategies. Dr. Neeraj Agarwal: Agree. So, let's now turn to the kidney cancer, starting with Abstract 4505, the final overall analysis from CheckMate-214 trial, which evaluated nivolumab plus ipilimumab, so dual checkpoint inhibition strategy, versus sunitinib in our patients with metastatic clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So, the final 9-year analysis of the phase 3 CheckMate-214 trial confirms the long-term superiority of nivolumab and ipilimumab over sunitinib for first-line treatment of advanced metastatic renal cell carcinoma. So, this has a median follow-up of 9 years. Overall survival remains significantly improved with the combination. So, in the ITT patient population, the intention-to-treat, the hazard ratio for overall survival was 0.71. So, this translates to a 29% reduction in the risk of death. 31% of patients were alive at this 108-month follow-up compared to 20% only in those who got sunitinib. So, similar benefits were observed in the intermediate- and poor-risk groups with a hazard ratio of 0.69, and 30% versus 19% survival at 108 months.  Importantly, a delayed benefit was also seen in those favorable-risk patients. So, the hazard ratio for overall survival improved from 1.45 in the initial report and now at 0.8 at 9 years follow-up, with 35% of patients alive at 108 months compared to 22% in those who got sunitinib. Progression-free survival also favored the nivo-ipi arm across all risk groups. At 96 months, the probability of remaining progression-free was about 23% compared to 9% in the sunitinib arm in the ITT patient population, 25% versus 9% in the intermediate- and poor-risk patients, and 13% compared to 11% in the favorable-risk patients. Importantly, at 96 months, 48% of patients in the nivo-ipi responders remained in response compared to just 19% in those who got sunitinib. And in the favorable-risk group, 36% of patients who responded remained in response, although data were not available for sunitinib in this subgroup.  So, this data reinforces the use of nivolumab and ipilimumab as a durable and effective first-line effective strategy for standard of care across all risk groups for advanced renal cell carcinoma. Dr. Neeraj Agarwal: Thank you, Jeanny. And of course, since ipi-nivo data were presented, several other novel ICI-TKI combinations have emerged. And I'm really hoping to see very similar data with TKI-ICI combinations down the line. It is really important to note that we are not seeing any new safety signals with the ICI combinations or ICI-based therapies, which is very reassuring given the extended exposure. Dr. Jeanny Aragon-Ching: Absolutely agree with you there, Neeraj.  Now, going on and moving on to Abstract 4514, which is the KEYNOTE-564 trial, and they reported on the 5-year outcomes of adjuvant pembrolizumab in clear cell RCC in patients who are at high risk for recurrence. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: Sure. So, the KEYNOTE-564 trial established pembrolizumab monotherapy as the first adjuvant regimen to significantly improve both disease-free survival and overall survival compared to placebo after surgery for patients with clear cell renal cell carcinoma. So, Dr Naomi Haas presented the 5-year update from this landmark trial.  A total of 994 patients were randomized to receive either pembrolizumab or placebo. The median follow-up at the time of this analysis was approximately 70 months. Disease-free survival remained significantly improved with pembrolizumab. The median DFS was not reached with pembrolizumab compared to 68.3 months with placebo, with a hazard ratio of 0.71, translating to a 29% reduction in risk of recurrence. At 5 years, 60.9% of patients receiving pembrolizumab remained disease-free compared to 52.2% with placebo. Overall survival also favored pembrolizumab. The hazard ratio for OS was 0.66, translating to a 34% reduction in risk of death, with an estimated 5-year overall survival rate of 87.7% with pembrolizumab compared to 82.3% for placebo. Importantly, these benefits were consistent across all key subgroups, including patients with sarcomatoid features. In addition, no new serious treatment-related adverse events have been reported in the 3 years since treatment completion.  So, these long-term data confirm pembrolizumab as a durable and effective standard adjuvant therapy for patients with resected, high-risk clear cell renal cell carcinoma. Dr. Jeanny Aragon-Ching: Thank you for that wonderful summary, Neeraj. Dr. Neeraj Agarwal: That wraps up our kidney cancer highlights. Any closing thoughts, Jeanny, before we conclude? Dr. Jeanny Aragon-Ching: It's been so wonderful reviewing these abstracts with you, Neeraj. So, the 2025 ASCO Annual Meeting showcased a lot of transformative data across GU cancers, from first-in-class bispecifics to long-term survival in RCC. And these findings are already shaping our clinical practices. Dr. Neeraj Agarwal: I agree. And we have covered a broad spectrum of innovations in GU cancers with strong clinical relevance.  So, thank you, Jeanny, for joining me today and sharing your insights.  And thank you to our listeners for joining us. You will find links to the abstracts discussed today in the transcript of this episode. If you find these conversations valuable, please take a moment to rate, review, and subscribe to the ASCO Daily News Podcast wherever you listen. Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Neeraj Agarwal     @neerajaiims     Dr. Jeanny Aragon-Ching   Follow ASCO on social media:       @ASCO on Twitter       ASCO on Bluesky   ASCO on Facebook       ASCO on LinkedIn       Disclosures:   Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono   Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis,    Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

中国人民银行与香港金融管理局于6月20日联合宣布，内地与香港快速支付系统互联互通（下称跨境支付通）将于6月22日正式上线。届时，两地居民仅凭收款方手机号码或银行账户，即可完成小额跨境汇款的实时到账操作，突破传统跨境汇款的时效限制。 当前，首批参与跨境支付通共12家，其中内地机构包括工、农、中、建、交五家国有大行以及招商银行；香港机构包括中银香港、东亚银行、建银亚洲、恒生银行、汇丰香港、工银亚洲，后续将逐步扩大参与范围。 02:13 跨境支付通：6月22号后的转账变革，速度与手续费的双重颠覆！ 05:26 招行和交行的转账体验对比：方便快捷但有限额 10:53 在四大上班，每个月给女儿汇款一万元生活费，养儿育女的现实与劝退 16:23 “信用卡额度限制：生活使用与投资之间的尴尬选择” 21:49 揭开CRS的神秘面纱：中国税务机关如何掌握境外信息 27:16 揭秘FATCA：美国与中国之间的双向信息交换机制 32:48 香港银行卡与人民币支付的便利性：在内地和香港之间的无缝连接 38:16 海外投资的机遇与挑战：普通百姓如何实现资产增值？ 43:42 创业者的必备心态：百万大火 Origin Story 49:10 A股投资策略：技术分析、基本面分析与基本面认知的重要性 54:39 投资理念与经历：在旅途中寻找优质股票的故事 01:00:04 情绪价值与实际收益：理财中的幻觉与现实差距

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

Anonymität ist heute ein immer rarer werdendes Gut. Aber wusstest du, dass es aktuell 88 Länder gibt, die nicht am internationalen Datenaustausch (CRS) teilnehmen? Wiederum aber, denn nur wenige Optionen sind wirklich praktikabel. Ich verrate dir meine Top 2 im gewohnten Podcast von „Faszination Freiheit“.

The Community Relations Service was created by the Civil Rights Act to smooth out race relations during desegregation, but like every government agency, it quickly took on a life of its own. The shadowy organization has an incredible level of secrecy and pushes woke agendas, including the normalization of trans kids and the planting of mosques in all Christian towns. Worst of all, the CRS is known to compel grieving families who are the victims of minority crime to deliver prepared statements downplaying the violence of their attackers. Academic Agent joins me to discuss.  Follow on: Apple: https://podcasts.apple.com/us/podcast/the-auron-macintyre-show/id1657770114 Spotify: https://open.spotify.com/show/3S6z4LBs8Fi7COupy7YYuM?si=4d9662cb34d148af Substack: https://auronmacintyre.substack.com/ Twitter: https://twitter.com/AuronMacintyre Gab: https://gab.com/AuronMacIntyre YouTube:https://www.youtube.com/c/AuronMacIntyre Rumble: https://rumble.com/c/c-390155 Odysee: https://odysee.com/@AuronMacIntyre:f Instagram: https://www.instagram.com/auronmacintyre/ Learn more about your ad choices. Visit megaphone.fm/adchoices

A review of the week's major US international tax-related news. In this edition:  US Senate moving forward on budget reconciliation legislation – Senate Finance Committee reports out nomination of new IRS Commissioner – President Trump increases tariffs on aluminum and steel imports – Treasury official warns US will act if OECD fails to accept US law as compliant with global minimum tax initiative – OECD releases CRS consolidated text for automatic exchange of financial account information in tax matters. 

On this episode of Ask The Expert, CRS's Visionary Founder Ashley Taylor discusses the company's rapid growth, the rising demand for contents restoration and how CRS is setting new industry standards through transparency and strategic alignment with carriers and TPAs.This episode is brought to you by:

Chronic sinusitis might be doing more than just clogging your nose–it could be clouding your brain. In this episode of Backtable ENT, Dr. Aria Jafari, an assistant professor at the University of Washington and co-director of the Neuroendocrinology Advanced Sinus and Skull-base Surgery Fellowship, discusses the connection between sinusitis and cognitive dysfunction with hosts Dr. Gopi Shah and Dr. Ashley Agan. --- SYNPOSIS Dr. Jafari shares how his interest in this field developed and details his research on the relationship between chronic rhinosinusitis (CRS) and brain function. The conversation highlights the comprehensive impact of sinus inflammation on overall health, emphasizing the importance of viewing CRS as a whole-body condition. They also discuss patient experiences, the methodologies used to assess cognitive dysfunction, potential treatments, and what's next in the research frontier.---TIMESTAMPS00:00 - Introduction 06:18 - The Impact of CRS on Quality of Life14:02 - Understanding Brain Fog and Cognitive Dysfunction24:29 - Pathophysiology and Theories of Cognitive Dysfunction27:44 - Chronic Inflammation and Cognitive Effects28:59 - Impact of Biologics on Cognitive Function31:28 - Risk Factors for Cognitive Dysfunction35:02 - Olfactory Symptoms 37:13 - Future Research and Treatment Approaches45:31 - Conclusion and Final Thoughts --- RESOURCES Dr. Aria Jafari https://www.uwmedicine.org/bios/aria-jafari

Episode Summary In this episode of the Canadian Immigration Podcast, host Mark Holthe and co-host Alicia Backman-Beharry unpack one of the most overlooked but impactful aspects of Express Entry: language testing. As one of the few areas where applicants can directly influence their CRS score, the language test often becomes the make-or-break factor in receiving an Invitation to Apply (ITA). Mark and Alicia take a deep dive into why language tests matter more than ever, how to choose the right test, and what pitfalls to avoid when entering your results into your Express Entry profile. They also examine the crucial role French proficiency now plays in Express Entry scoring, especially in the context of category-based draws and the federal government's push for Francophone immigration. Whether you're building your Express Entry profile or trying to increase your CRS score, this episode offers a detailed, practical guide to getting it right—before you risk a refusal or misrepresentation allegation. Key Topics Discussed The Power of Language Tests in Express Entry Why language test scores are one of the most controllable and impactful factors in your CRS score. How they affect eligibility under CEC, FSW, and category-based draws. Examples of missed opportunities due to expired or invalid test results. Approved Tests and Common Pitfalls A breakdown of approved English and French tests: CELPIP, IELTS (General), PTE Core, TEF, and TCF. Key differences between test formats and how they affect your performance. Why using the wrong version (e.g., IELTS Academic) can invalidate your score. Test Validity and Expiry Rules How long your test results are valid (and what date counts). What happens if your results expire between your ITA and eAPR. When to retake the test to avoid losing points—or your application. CRS Boosting Strategies The significance of CLB 7 and CLB 9: minimum thresholds vs. competitive scoring. The points advantage of adding French as a second language (up to 74 extra points). How dual-language applicants can outperform others in a tight draw environment. Data Entry and Misrepresentation Risks How to correctly input test codes, registration numbers, and scores in your profile. The hidden dangers of typing errors and mismatched documentation. What to do if your test expires mid-application. Retesting and Test Selection Strategy Why retaking a test can make a meaningful difference. Choosing between CELPIP, IELTS, and PTE based on format, availability, and your strengths. How to leverage test prep and targeted coaching to improve scores. Key Takeaways Language tests are one of the best ways to increase your CRS score quickly and legally. Accuracy matters: a small data entry error can cost you your ITA—or worse. CLB 9 opens the door to significant bonus points through skill transferability. French proficiency is now a game-changer under category-based draws. Retesting and preparation are strategic tools, not just last-ditch efforts. Quotes from the Episode Mark Holthe: "If there's one part of your Express Entry profile that you can control—and improve—it's your language test score." Alicia Backman-Beharry: "People miss out on invitations every week because of expired scores or invalid test versions. Don't let that be you." Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Enroll in the Express Entry Accelerator and Masterclass Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

JoePat Roop recently sat down with Duane Allen, the lead singer of the iconic country gospel band, the Oak Ridge Boys. They discuss the band's legacy, Duane's personal experiences in the music industry, and reflections on retirement and continuing to perform. The conversation highlights the importance of enjoying life and the challenges of transitioning in the music world, especially after the loss of band members. Duane shares insights into the band's future plans and their ongoing commitment to their fans. For more information or to schedule a consultation call 704-946-7000 or visit www.belmont-capital.com! Follow us on social media: YouTube | Instagram | Facebook | LinkedInSee omnystudio.com/listener for privacy information.

Since firing head coach Lorne Donaldson at the end of April, things haven't gotten any better for the Chicago Stars. In fact, they may haven only gotten worse. After a 0-0 draw in New Jersey, the Stars have lost their last three in a row and are adrift at the bottom of the NWSL table. Will things get better any time soon? Off the field, general manager Richard Feusz definitely said some stuff, Mallory Swanson is pregnant, and the Stars are going to play a game at Northwestern's ramshackle soccer-turned football lakefront stadium. It's a lot to get through, most of it not good, and Alex is once again joined by Lesley Ryder of Gal Pal Sports to go over it all. Oh, and did we mention Alyssa Naeher's hurt now?

 Select Express Entry Pick bearing Intake number 346 on May 12, 2025 for Provincial Nominee Program  Good day ladies and gentlemen, this is IRC news, and I am Joy Stephen, an authorized Canadian Immigration practitioner bringing out this Express Entry Pick. I am coming to you from the Polinsys studios in Cambridge, Ontario Latest Express Entry Pick Information: Round Number: 346 Date: May 12, 2025 Number of Invitations: 511 Lowest CRS Score: 706 Category: Provincial Nominee Program This selection is for candidates nominated by a province. If your CRS score is 706 or above, you should have received your invitation. Some candidates with a score of 706 may also have received an invitation, depending on when their profile was submitted. You can always access past Express Entry picks by visiting this link: https://myar.me/tag/EEP/  Furthermore, if you are interested in gaining comprehensive insights into the Provincial Express Entry Federal pool Canadian Permanent Residence Program or other Canadian Federal or Provincial Immigration programs, or if you require guidance after your selection, we cordially invite you to connect with us through  https://myar.me/c  We highly recommend participating in our complimentary Zoom resource meetings, which take place every Thursday. We kindly request you to carefully review the available resources. Should any questions arise, our team of Canadian Authorized Representatives is readily available to address your concerns during the weekly AR's Q&A session held on Fridays. You can find the details for both of these meetings at https://myar.me/zoom.  Our dedicated team is committed to providing you with professional assistance throughout the immigration process. Additionally, IRCNews offers valuable insights on selecting a qualified representative to advocate on your behalf with the Canadian Federal or Provincial governments, which can be accessed at https://ircnews.ca/consultant 

Select Express Entry Pick bearing Intake number 347 on May 13, 2025 for Canadian Experience Class Good day ladies and gentlemen, this is IRC news, and I am Joy Stephen, an authorized Canadian Immigration practitioner bringing out this Express Entry Pick. I am coming to you from the Polinsys studios in Cambridge, OntarioLatest Express Entry Pick Information:Round Number: 347 Date: May 13, 2025 Number of Invitations: 500 Lowest CRS Score: 547 Category: Canadian Experience ClassThis selection targets candidates with Canadian work experience. If your CRS score is 547 or higher, you should have received your invitation. Some candidates with a score of 547 may also have received one, depending on when their profile was submitted.You can always access past Express Entry picks by visiting this link: https://myar.me/tag/EEP/ Furthermore, if you are interested in gaining comprehensive insights into the Provincial Express Entry Federal pool Canadian Permanent Residence Program or other Canadian Federal or Provincial Immigration programs, or if you require guidance after your selection, we cordially invite you to connect with us through  https://myar.me/c  We highly recommend participating in our complimentary Zoom resource meetings, which take place every Thursday. We kindly request you to carefully review the available resources. Should any questions arise, our team of Canadian Authorized Representatives is readily available to address your concerns during the weekly AR's Q&A session held on Fridays. You can find the details for both of these meetings at https://myar.me/zoom. Our dedicated team is committed to providing you with professional assistance throughout the immigration process. Additionally, IRCNews offers valuable insights on selecting a qualified representative to advocate on your behalf with the Canadian Federal or Provincial governments, which can be accessed at https://ircnews.ca/consultant 

In this month's episode, Chris Capewell, Anthony Mourginos and Saoirse Finnegan provide updates on FARs, Corporate Governance & AML Compliance, VASP Regime, and CRS, as well as a reminder on Beneficial Ownership.SPEAKERS:Chris Capewell, Partner | +1 345 814 5666 | chris.capewell@maples.com | View bioAnthony Mourginos | Partner | +1 345 814 5155 | anthony.mourginos@maples.com | View bioSaoirse Finnegan | Assistant Vice President | +1 345 814 6144 | saoirse.finnegan@maples.comRESOURCES:Click here for Episode 20 Presentation slidesRelated Services:Maples Group Regulatory and Financial Services AdvisoryWith a depth of experience across all regulated sectors, the Maples Group Regulatory and Financial Services team is positioned to address client needs and sensitivities. We have the largest dedicated Cayman Islands Regulatory and Financial Services team in the offshore market.Follow Us: LinkedIn: https://www.linkedin.com/company/maplesgroup/Instagram: https://www.instagram.com/maplesgroup/Twitter: https://twitter.com/maplesgroupFacebook: https://www.facebook.com/maplesgroup/Website: https://maples.com/podcasts/15-15

How can embedding the booking engine and reintroducing voice finally tip the scales for direct bookings?In this episode of dojo.live, we welcome back Josh Graham, Head of Marketing Development for North America at Cloudbeds. This conversation explores the future of direct bookings and digital storefront innovation, with a spotlight on Cloudbeds' embedded booking engine and their AI concierge solution, Engage. From voice-assisted reservations to the power of Google Tag Manager, Josh unpacks how simplifying the guest's path to purchase—and enabling end-to-end journey tracking without data gaps—is helping hotels dramatically improve conversion and loyalty, while also optimizing marketing performance and user experience more effectively.After 10 years in hotel operations at branded and independent hotels in Washington, D.C., Josh Graham transitioned to technology at TravelClick. Over 13 years, he held a number of senior sales, marketing, and go-to-market roles, working with CRS, Business Intelligence, and e-commerce/digital marketing. In his final role, he served as Regional VP for their guest management/CRM product.Following TravelClick's acquisition by Amadeus in 2018, Josh joined Revenue Analytics in 2020 to help launch their RMS solution, N2Pricing. After roles at Salesforce in their Travel and Hospitality unit and FLYR for Hospitality, Josh found his home at Cloudbeds. As Head of Market Development for North America, he drives market awareness and introduces Cloudbeds to new hotelier segments.About Josh

Lorne Donaldson has been fired as head coach of Stars FC, in a surprising move that's shaking up the club. The CHGO Stars crew breaks down in this emergency pod to what led to Donaldson's dismissal, the team's recent performance, and what's next for the Stars. Who could be the next head coach, and how will this affect the squad in the future? Don't miss our full Stars FC coaching change analysis, reactions, and insider breakdown! 

Kent Redding's path from retail mogul to real estate powerhouse isn't what you'd expect - especially when leadership, empathy, and branding collide. In this episode, Kent shares the surprising lessons he learned that still shape his business today. You'll walk away rethinking what it really means to build trust, show up, and lead with heart. Plus, don't miss the story of the open house that literally caused a traffic jam.   Key takeaways to listen for How Kent turned personal values into a business branding strategy that stuck What managing 400 retail employees teaches you about long-term client loyalty The marketing wisdom that still drives Kent's success today Reasons self-awareness and empathy matter more than market trends Is volunteering with your local REALTOR® association a great career move?   About Kent ReddingKent is a top-producing REALTOR®, 2024 President of the Austin Board of REALTORS®, and a 20-year veteran with Berkshire Hathaway. Known for his client-first approach, Kent combines entrepreneurial grit with a deep commitment to the community. He's a ten-time Platinum Top 50 award winner and holds designations including GRI, CRS, ABR, ePro, MRP, and CLHMS. Outside of real estate, Kent volunteers with groups like Community First! Village, Hungry Souls, and Red Oak Hope.   Connect with Kent Website: Kent Redding Facebook: Kent Redding | Kent Redding Team Instagram: @kentreddinggroup LinkedIn: Kent Redding Email: kent@callkent.com Contact Number: (512) 797-5737   Connect with LeighPlease subscribe to this podcast on your favorite podcast app at https://pod.link/1153262163, and never miss a beat from Leigh by visiting https://leighbrown.com. DM Leigh Brown on Instagram @ LeighThomasBrown.   Sponsors"You Ask. Leigh Answers." Your Affordable Coaching ProgramHey there, real estate pros! Are you ready for some more Leigh Brown wisdom in your life? Then don't miss out on my brand-new program, "You Ask. Leigh Answers." It's your exclusive gateway to the insights and advice you need to supercharge your real estate business. With "You Ask. Leigh Answers." you get Direct Access to Leigh Brown, directly! Expert Coaching, Community Connection, and Extensive Resources. Whether listening to this on the go or watching at home, sign up today at Answers.RealEstate and take your business to the next level. Trust me, you'll be glad you did!  

Well, the Chicago Stars did win for the first time this season back on April 13th at Bay FC! Unfortunately they've lost the two since without scoring a single goal. Are the team's problem's fixable? Would even the return of Mallory Swanson do anything to help? Things don't get any easier with Gotham, the Spirit and Current all on tap in May. Then, Tara from the Scuffed Podcast and their recently launched ‘Boots on the Ground' podcast focusing on the US Women's National Team and the NWSL joins the show to check in on news and notes from the last month. An ALLCITY Network Production PARTY WITH US: https://bit.ly/3SRS03z ALL THINGS CHGO: https://linktr.ee/chgosports WATCH YOUR FAVORITE TEAMS: https://www.fubotv.com/chgo Empire Today: Schedule a free in-home estimate today! All listeners can receive a $350 OFF discount when they use the promo code CHGO. Restrictions apply. See https://empiretoday.com/chgo for details. Ray Auto Group: Get into your next vehicle with Ray Auto in Fox Lake! Ray Chevy: https://www.raychevrolet.com/ Ray CDJR: https://www.raycdjr.com/ Sunnyside Cannabis Dispensary: Head to https://sunnyside.shop and use code ‘HICHGO' at checkout for 50% off your first 3 online orders on our favorite brands like Cresco, Good News, & more to elevate your first purchase! Sunnyside* Cannabis Dispensary -Bright buys, every day. Only for 21+ or IL medical card holders Get Coors Light delivered straight to your door with Instacart by going to https://coorslight.com/CHGOGoal. Celebrate Responsibly. Coors Brewing Company, Golden, Colorado. Download the Gametime app, create an account, and use code CHGO for $20 off your first purchase. When you shop through links in the description, we may earn affiliate commissions. Copyright Disclaimer under section 107 of the Copyright Act 1976, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, education and research. Fair use is a use permitted by copyright statute that might otherwise be infringing. #ChicagoRedStars #RedStars #WithTheStars

Episode Summary In this essential episode of the Canadian Immigration Podcast, Mark Holthe and Alicia Backman-Beharry return with another instalment in the Express Entry “Getting it Right” series—this time focusing on physicians and healthcare professionals. While doctors may excel in their field, navigating Canadian immigration law is a whole different beast. Mark and Alicia explore the unique challenges medical professionals face in Express Entry applications—from the pitfalls of choosing the wrong ECA organization, to confusion around Canadian spouses, unpaid internships, and self-employed work experience. They also dig into the April 2023 policy change that allows self-employed physicians to finally claim Canadian work experience under CEC—if done correctly.

Où, en compagnie de Jeff, Dan, Jean-Hubert, Candice et de son -nouveau- petit protégé, Bertrand, il sera question pêle-mêle du temple de l’Ordre Solaire, du Printemps de Bourges, de CRS et de plein d’autres choses passionnantes! On vous souhaite donc courage, patience et abnégation pour affronter ce nouvel épisode de Welcome! L'article Welcome! du 19 avril 2025 est apparu en premier sur Radio Campus Tours - 99.5 FM.

Congress holds the power of the purse. The United States Government is the largest business in the world, but to conduct business - and national security - Congress has to approve the funds and the money. Representative Jake Ellzey is now a 3-term Congressman representing Texas's 6th District. He's a Naval Academy graduate, a helicopter and fighter pilot, and a member of the House Appropriations Committee, where his decisions determine what the government funds and what it doesn't. He's also the co-chair of the bipartisan military Veterans alliance, the For Country Caucus. With the American government changing at lightning pace, Fran Racioppi asked the Congressman how the Appropriations Committee is prioritizing funding, what that means for national defense, rooting out fraud, waste and abuse; and if there's ever a way for America to balance the budget and stop overspending. Representative Ellzey also shares why we need to clearly define America's next battlefield, funding military readiness and innovation to combat both nation-state adversaries and terror groups, and the critical role he sees our Special Operations Forces playing in the grey war the United States is now in. Plus he shares his leadership lessons from the cockpit and the deck of the USS Ronald Reagan to the halls of Congress.Watch, listen or read our conversation from Congressman Ellzey's office. Don't miss our full coverage from Capitol Hill. Special thanks to For Country Caucus for setting up this series. Highlights0:00 Introduction6:20 Veterans in Congress9:12 Why the Navy?10:50 The Appropriations Committee14:45 Funding Executive Orders17:24 DOGE's impact22:41 Funding Military Readiness25:35 Role of SOF in the next conflict27:20 The sentiment of America31:50 Shout out to Green Berets34:08 Defining the Battlefield38:18 Why Was There An Open Border Policy39:44 Can America Balance The Budget?40:42 Is America Ready?42:41 Military Lessons Taken To CongressKey Quotes:“There's a thing about veterans: it really doesn't matter which era, what your uniform, or how well you know somebody who's a veteran…Nobody else gets into that world.”“With SEALS, Green Berets, most pilots; tell me I can't do something, and then watch.”“CR's are bad. Year-long CRs are terrible. Specifically for defense.” “Once we know what the priorities of the President are, we're not going to put something on the floor that ultimately he's not going to sign.”“It's broken. So let's break it. Let's break the whole thing.”“There's not enough money to do everything we need to do to be completely ready.” “It's absolutely essential that our adversaries know that we've got the best in the world.”“The sentiment of Americans is we're strong again, we're not to be trifled with, if you attack us, we're going to hammer you.”“I'm a huge fan of Green Berets.”“I see weapons of mass destruction as the compounds that are making Fentanyl.” “Never pass up the opportunity to shut up.”Follow the Jedburgh Podcast and the Green Beret Foundation on social media. Listen on your favorite podcast platform, read on our website, and watch the full video version on YouTube as we show why America must continue to lead from the front, no matter the challenge.The Jedburgh Podcast and the Jedburgh Media Channel are an official program of The Green Beret Foundation.The opinions presented on the The Jedburgh Podcast and the Jedburgh Media Channel are the opinions of my guests and myself. They do not necessarily reflect the opinions of the Green Beret Foundation and the Green Beret Foundation assumes no liability for their accuracy, nor does Green Beret Foundation endorse any political candidate or any political party.

As bispecific therapies become more available in the outpatient setting, community oncology practices are adapting to support safe and effective treatment.In this CE episode, we sit down with Nick Bouchard, PharmD, Director of Pharmacy Services at Hematology Oncology Associates of Central New York (HOACNY), to explore how his team built a successful outpatient bispecific therapy program from the ground up.Nick offers real-world insight into how his community oncology practice is proactively managing side effects like CRS and ICANS, improving patient experiences, and reducing hospital admissions. From navigating flexible dosing schedules to coordinating across the care team, this episode highlights the strategies that are making a meaningful difference in patient-centered care.

No more CRs. We need a real budget. Imperfect bills are still necessary, no such thing as perfection. See omnystudio.com/listener for privacy information.

In this episode, Bernie and Anthony are joined by 3 hematology pharmacists - James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; and Justine Preedit, PharmD, BCOP - to discuss the optimal management of CRS in patients receiving bispecific antibodies!Inspired by this recent paper:https://www.nature.com/articles/s41408-025-01222-y

Frankie Guida had the chance to attend the Country Radio Seminar in Nashville on February 19th-21st. He sat down with up-and-coming artists Chase Matthew, Hudson Westbrook & Redferrin. Chase Matthew discussed his biggest musical influences, collaborations he dreams about, and what’s next for him in the near future. Hudson Westbrook, who broke into the music scene thanks to a viral video of him performing his song “Take It Slow,” talked about how country music became his escape and the sacrifices he’s made to chase his dreams. Redferrin spoke about his friendship with Florida-Georgia Line, how his motocross background shaped his grit in the industry and why storytelling is at the heart of everything he does. Schedule a complimentary appointment: A Better Way Financial CLICK HERE to register for one of our upcoming Tax-Smart Retirement Planning Dinner Workshops. Read our book! Amazon Best Seller, “The Book on Retirement: A Better Way to Stretch Your Retirement Dollars While Living the Lifestyle of Your Dreams.” Follow us on social media: Facebook | LinkedIn | YouTube See omnystudio.com/listener for privacy information.

If you've ever wondered what the view from the International Space Station might look like in real-time, this is your episode. Or if you just want to know more about who's up there and what's going on at the ISS on a particular day, this is it. Liam Kennedy, the one and only Space TV Director, is with us. Liam has been working to bring content and video from the ISS down to earth for over a decade, and it's all come together just this year! Liam invented ISS Above, a Raspberry Pi-driven system that highlights key information about the space station in real-time. Join us for this special look at the view from on high! Headlines: NASA is cutting $420 million in contracts, as confirmed by NASA press secretary Bethany Stevens. Boeing Starliner's next crewed launch was delayed to late 2025 / early 2026 due to ongoing helium leaks and thruster issues. Northrop Grumman's Cygnus cargo mission (CRS-22) was canceled after the spacecraft was damaged during shipping; it will be rescheduled to CRS-23 in the fall. Historic FRAM 2 mission launching March 31 - first human spaceflight over Earth's poles, financed by Maltese cryptocurrency entrepreneur Chun Wang. The Blue Origin launch date with Katy Perry, the first all-female mission since Valentina Tereshkova's solo flight, is set for April 14. A partial solar eclipse will be visible over northern US and Canada on March 29. Main Topic - Interview with Liam Kennedy Liam Kennedy's space journey began at age 6, watching the Apollo 11 moon landing, leading to becoming president of Orange County Astronomers and developing ways for the public to experience the Overview Effect. ISS Above is a Raspberry Pi device created in 2013 that tracks the ISS and lights up when it passes overhead, and is now in 5,000 locations worldwide. Kennedy partnered with SEN, founded by Charles Black, to create high-quality 4K cameras for the ISS after NASA's HDEV camera system stopped transmitting in 2019. SEN provides free live streaming of Earth from space via YouTube and SEN.com, generating revenue through advertising and clip licensing. The Space TV camera system includes six cameras on the Columbus module of the ISS, showcasing docking ports, Earth views, and the horizon. Space TV offers dramatically higher quality than NASA's existing cameras and captured stunning 4K footage of Boeing Starliner's undocking and Crew Dragon flights. SEN plans to expand with more cameras and locations, including potential deployment on future commercial space stations and lunar missions. Kennedy discusses the "Overview Effect" - how seeing Earth from space creates a transformative perspective that inspires action on Earth. The ISS Above Experience will be featured at the Space Symposium to celebrate the 25th anniversary of continuous human presence on the ISS. Hosts: Rod Pyle and Tariq Malik Guest: Liam Kennedy Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit

If you've ever wondered what the view from the International Space Station might look like in real-time, this is your episode. Or if you just want to know more about who's up there and what's going on at the ISS on a particular day, this is it. Liam Kennedy, the one and only Space TV Director, is with us. Liam has been working to bring content and video from the ISS down to earth for over a decade, and it's all come together just this year! Liam invented ISS Above, a Raspberry Pi-driven system that highlights key information about the space station in real-time. Join us for this special look at the view from on high! Headlines: NASA is cutting $420 million in contracts, as confirmed by NASA press secretary Bethany Stevens. Boeing Starliner's next crewed launch was delayed to late 2025 / early 2026 due to ongoing helium leaks and thruster issues. Northrop Grumman's Cygnus cargo mission (CRS-22) was canceled after the spacecraft was damaged during shipping; it will be rescheduled to CRS-23 in the fall. Historic FRAM 2 mission launching March 31 - first human spaceflight over Earth's poles, financed by Maltese cryptocurrency entrepreneur Chun Wang. The Blue Origin launch date with Katy Perry, the first all-female mission since Valentina Tereshkova's solo flight, is set for April 14. A partial solar eclipse will be visible over northern US and Canada on March 29. Main Topic - Interview with Liam Kennedy Liam Kennedy's space journey began at age 6, watching the Apollo 11 moon landing, leading to becoming president of Orange County Astronomers and developing ways for the public to experience the Overview Effect. ISS Above is a Raspberry Pi device created in 2013 that tracks the ISS and lights up when it passes overhead, and is now in 5,000 locations worldwide. Kennedy partnered with SEN, founded by Charles Black, to create high-quality 4K cameras for the ISS after NASA's HDEV camera system stopped transmitting in 2019. SEN provides free live streaming of Earth from space via YouTube and SEN.com, generating revenue through advertising and clip licensing. The Space TV camera system includes six cameras on the Columbus module of the ISS, showcasing docking ports, Earth views, and the horizon. Space TV offers dramatically higher quality than NASA's existing cameras and captured stunning 4K footage of Boeing Starliner's undocking and Crew Dragon flights. SEN plans to expand with more cameras and locations, including potential deployment on future commercial space stations and lunar missions. Kennedy discusses the "Overview Effect" - how seeing Earth from space creates a transformative perspective that inspires action on Earth. The ISS Above Experience will be featured at the Space Symposium to celebrate the 25th anniversary of continuous human presence on the ISS. Hosts: Rod Pyle and Tariq Malik Guest: Liam Kennedy Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit

If you've ever wondered what the view from the International Space Station might look like in real-time, this is your episode. Or if you just want to know more about who's up there and what's going on at the ISS on a particular day, this is it. Liam Kennedy, the one and only Space TV Director, is with us. Liam has been working to bring content and video from the ISS down to earth for over a decade, and it's all come together just this year! Liam invented ISS Above, a Raspberry Pi-driven system that highlights key information about the space station in real-time. Join us for this special look at the view from on high! Headlines: NASA is cutting $420 million in contracts, as confirmed by NASA press secretary Bethany Stevens. Boeing Starliner's next crewed launch was delayed to late 2025 / early 2026 due to ongoing helium leaks and thruster issues. Northrop Grumman's Cygnus cargo mission (CRS-22) was canceled after the spacecraft was damaged during shipping; it will be rescheduled to CRS-23 in the fall. Historic FRAM 2 mission launching March 31 - first human spaceflight over Earth's poles, financed by Maltese cryptocurrency entrepreneur Chun Wang. The Blue Origin launch date with Katy Perry, the first all-female mission since Valentina Tereshkova's solo flight, is set for April 14. A partial solar eclipse will be visible over northern US and Canada on March 29. Main Topic - Interview with Liam Kennedy Liam Kennedy's space journey began at age 6, watching the Apollo 11 moon landing, leading to becoming president of Orange County Astronomers and developing ways for the public to experience the Overview Effect. ISS Above is a Raspberry Pi device created in 2013 that tracks the ISS and lights up when it passes overhead, and is now in 5,000 locations worldwide. Kennedy partnered with SEN, founded by Charles Black, to create high-quality 4K cameras for the ISS after NASA's HDEV camera system stopped transmitting in 2019. SEN provides free live streaming of Earth from space via YouTube and SEN.com, generating revenue through advertising and clip licensing. The Space TV camera system includes six cameras on the Columbus module of the ISS, showcasing docking ports, Earth views, and the horizon. Space TV offers dramatically higher quality than NASA's existing cameras and captured stunning 4K footage of Boeing Starliner's undocking and Crew Dragon flights. SEN plans to expand with more cameras and locations, including potential deployment on future commercial space stations and lunar missions. Kennedy discusses the "Overview Effect" - how seeing Earth from space creates a transformative perspective that inspires action on Earth. The ISS Above Experience will be featured at the Space Symposium to celebrate the 25th anniversary of continuous human presence on the ISS. Hosts: Rod Pyle and Tariq Malik Guest: Liam Kennedy Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit

If you've ever wondered what the view from the International Space Station might look like in real-time, this is your episode. Or if you just want to know more about who's up there and what's going on at the ISS on a particular day, this is it. Liam Kennedy, the one and only Space TV Director, is with us. Liam has been working to bring content and video from the ISS down to earth for over a decade, and it's all come together just this year! Liam invented ISS Above, a Raspberry Pi-driven system that highlights key information about the space station in real-time. Join us for this special look at the view from on high! Headlines: NASA is cutting $420 million in contracts, as confirmed by NASA press secretary Bethany Stevens. Boeing Starliner's next crewed launch was delayed to late 2025 / early 2026 due to ongoing helium leaks and thruster issues. Northrop Grumman's Cygnus cargo mission (CRS-22) was canceled after the spacecraft was damaged during shipping; it will be rescheduled to CRS-23 in the fall. Historic FRAM 2 mission launching March 31 - first human spaceflight over Earth's poles, financed by Maltese cryptocurrency entrepreneur Chun Wang. The Blue Origin launch date with Katy Perry, the first all-female mission since Valentina Tereshkova's solo flight, is set for April 14. A partial solar eclipse will be visible over northern US and Canada on March 29. Main Topic - Interview with Liam Kennedy Liam Kennedy's space journey began at age 6, watching the Apollo 11 moon landing, leading to becoming president of Orange County Astronomers and developing ways for the public to experience the Overview Effect. ISS Above is a Raspberry Pi device created in 2013 that tracks the ISS and lights up when it passes overhead, and is now in 5,000 locations worldwide. Kennedy partnered with SEN, founded by Charles Black, to create high-quality 4K cameras for the ISS after NASA's HDEV camera system stopped transmitting in 2019. SEN provides free live streaming of Earth from space via YouTube and SEN.com, generating revenue through advertising and clip licensing. The Space TV camera system includes six cameras on the Columbus module of the ISS, showcasing docking ports, Earth views, and the horizon. Space TV offers dramatically higher quality than NASA's existing cameras and captured stunning 4K footage of Boeing Starliner's undocking and Crew Dragon flights. SEN plans to expand with more cameras and locations, including potential deployment on future commercial space stations and lunar missions. Kennedy discusses the "Overview Effect" - how seeing Earth from space creates a transformative perspective that inspires action on Earth. The ISS Above Experience will be featured at the Space Symposium to celebrate the 25th anniversary of continuous human presence on the ISS. Hosts: Rod Pyle and Tariq Malik Guest: Liam Kennedy Download or subscribe to This Week in Space at https://twit.tv/shows/this-week-in-space. Join Club TWiT for Ad-Free Podcasts! Support what you love and get ad-free shows, a members-only Discord, and behind-the-scenes access. Join today: https://twit.tv/clubtwit

Two games into the NWSL season and things couldn't be going much worse for the soccer team formerly known as the Chicago Red Stars. An underwhelming rebrand, lack of reinforcements and absent Mallory Swanson led into what's been a terrible start on the field. Alex recaps a drubbing in Orlando and blown lead at home before being joined by Lesley Ryder of Gal Pal Sports and Defector to commiserate.

Jim Fox sits down with country music star Chancey Williams from CRS in Nashville. Ready to connect with Jim today? Get some Financial Straight Talk!See omnystudio.com/listener for privacy information.

In Episode #55 of Sippin' On Country, we sit down with Garrett Bradford, a talented country artist known for his heartfelt music and storytelling. We dive into his journey of finding his voice in Nashville, the inspiration behind his songs, and what it's like to make a name for himself in the competitive country music scene. Recorded live at CRS 2025, Garrett shares his experiences in the city and what's ahead for him in 2025!Here are the official social media profiles and website for Garrett Bradford:Official Website: garrettbradford.comInstagram: @garrettbradfordmusicTikTok: @garrettbradfordtxThreads: @garrettbradfordmusicFacebook: Garrett BradfordYouTube: Garrett Bradford Hosted on Acast. See acast.com/privacy for more information.

Episode Summary In this episode of the Canadian Immigration Podcast, host Mark Holthe and co-host Alicia Backman-Beharry tackle one of the most critical yet frequently misunderstood aspects of Express Entry applications: proving work experience. With refusals on the rise, Mark and Alicia walk you through the common mistakes applicants make when submitting reference letters and employment documents—and how to avoid them. They dive deep into the essential elements of a strong reference letter, including what must be included, what officers look for, and how to handle situations where you can't get the perfect letter. Whether you're applying under the Canadian Experience Class (CEC), Federal Skilled Worker Program (FSW), or navigating category-based draws, this episode is a must-listen for anyone serious about avoiding rejection and maximizing CRS points.

From autopens to CRs, Democrats appear to have forgotten everything they ever knew about politics. Andrew Malcolm and I discuss the basics that have been forgotten and why Donald Trump needs to learn a lesson from it. Chuck Schumer's humiliation won't be the last for Democrats.

Send us a textThe U.S. House passed a Continuing Resolution this week. In the aftermath, Thomas Massie and Donald Trump got into a dustup on X. It raised questions about Massie and his voting record, so Hannah takes a moment to clear the air about Massie's voting record, his votes on CRs in the past, and what Massie actually wants to see in a spending bill. In this week's Homeschool Hints segment, Hannah is once again joined by her Mom, Carlotta Jackson, to discuss what a homeschool day looked like in their home growing up. With nine children, two with special needs, and a myriad of extra curricular activities, what did the average day look like in the Jackson homeschool? https://www.thehannahmillershow.com/podcasts/https://bobslone.com/contact/bob@bobslone.com

Host Tracey Hawkins delves into the critical role of negotiation leverage in real estate transactions, focusing on how to protect your client's interests at the negotiating table. Joined by experts Matthew Rathbun and Amy Steele, discover key strategies to avoid common pitfalls, safeguard your client's bargaining power and enhance your negotiation skills. Learn about the impact of digital security, social media and AI on real estate transactions, and gain practical tips to ensure both safety and success.   Meet the Guests  Matthew Rathbun, ABR, CRS, is a broker with Coldwell Banker Elite in Fredericksburg, Virginia. He serves as the 2025 president-elect of the Fredericksburg Area Association of REALTORS® and the 2025 president of the Real Estate Business Institute (REBI), an NAR affiliate organization. Rathbun is an instructor of NAR's Real Estate Negotiation Expert (RENE) certification course.  Amy Steele, ABR, SRS, is an agent with JPAR Real Estate in Grapevine, Texas, who also is licensed in California. The owner of a short-term rental property, Steele focuses her real estate expertise on investment properties and vacation homes. She has a personal library of more than 3,000 books. 

In this episode of Good Morning Liberty, hosts Nate and Charles dive into a range of topics including the importance of positive mindset, recent protests at Trump Tower, the complexities surrounding a green card holder accused of terrorist support, and the looming government shutdown. They also discuss the potential elimination of taxes for earners under $150k and the ongoing dismantling of the Department of Education. Fueled by discussions on taxation, free speech, and government spending, this episode offers a comprehensive analysis of current events and political strategies. (01:57) Protesters Storm Trump Tower (02:45) Debate on Private Property Rights (03:20) Columbia Student Deportation Controversy (11:09) Government Shutdown Drama (20:32) Political Strategy and Government Shutdowns (21:57) Schumer's Shutdown Warning (22:37) Broad Category Funding and CRs (23:42) Military's Perspective on Shutdowns (24:04) Critique of Republican Strategy (24:28) Dismantling the Department of Education (26:08) Trump's Tax Elimination Proposal (27:40) The True Cost of Government Spending   Links:   https://gml.bio.link/   YOUTUBE:   https://bit.ly/3UwsRiv   RUMBLE:   https://rumble.com/c/GML   Check out Martens Minute!   https://martensminute.podbean.com/   Follow Josh Martens on X:   https://twitter.com/joshmartens13   Join the private discord & chat during the show!   joingml.com   Bank on Yourself bankonyourself.com/gml   Get FACTOR Today! FACTORMEALS.com/factorpodcast     Good Morning Liberty is sponsored by BetterHelp! Rediscover your curiosity today by visiting Betterhelp.com/GML (Get 10% off your first month)     Protect your privacy and unlock the full potential of your streaming services with ExpressVPN. Get 3 more months absolutely FREE by using our link EXPRESSVPN.com/GML  

We're getting rowdy with Ira Dean, the hit songwriter, artist, and all-around country music outlaw!

We wanna hear from you! Send us a message here :) CRS 2025 with Charly Reynolds & The Swon Brothers! Charly Reynolds is a rising star in country music, captivating audiences with her authentic storytelling and vibrant sound. At just 25 years old, the Florida native has quickly established herself as a formidable singer- songwriter, with her debut album Off The Record showcasing a blend of Nashville twang and Texas dance hall charm. Released on September 20, 2024, the album features four compelling singles: “Love You Long,” "Somebody In Love,” “People Think,” and “Visiting Hours,” each offering a glimpse into Charly's relatable experiences and heartfelt lyrics. Stay connected with her here!Known for their seamlessly smooth, tight-knit sibling harmonies, The Swon Brothers were thrilling audiences long before their appearance as finalists on NBC's The Voice. Honored with the “Rising Star” award by the Oklahoma Music Hall of Fame and inducted into the “Rhythm and Routes Oklahoma Music Trail,” the Muskogee, OK natives have been charming fans with their fun-loving personalities since childhood. Since releasing their major label hit, “Later On,” the brothers have written and produced their own music independently and also contributed to superstar Blake Shelton's album BODY LANGUAGE, co-writing the title track and appearing as featured performers on the song. During their career the brothers have garnered industry honors and nominations with nods from The Country Music Association, The Academy of Country Music and The CMT Music Awards. Stay connected with the guys here!Support the show

As you have probably heard in the news over the past month or so, the Trump administration has frozen foreign aid programs and essentially dismantled USAID, which is the federal government's overseas humanitarian relief agency. These decisions have had an enormous impact on the work of both faith-based and secular nonprofit organizations doing humanitarian work, including Catholic ones. Our guest today, Bill O'Keefe, is one of the top executives at Catholic Relief Services, which is the official overseas humanitarian agency of the American Catholic community. Since their founding over 80 years ago, CRS has grown to serve communities in poverty in more 100 countries around the world. Bill has served at CRS for 38 years, and today he is the agency's Executive Vice President for Mission, Mobilization and Advocacy. In addition to advocating on in Washington, DC, for robust U.S. foreign aid funding, Bill mobilizes CRS' supporters across the country in a shared mission to support the world's most vulnerable people. There is probably no single person in the country who knows as much as Bill does about how the gutting of the US government's foreign aid programs will affect the US Church's ability to help people across the globe. Host Mike Jordan Laskey found it so informative and helpful to talk to Bill. But it was also incredibly upsetting. People will die because of these decisions. The US Catholic Church's immense humanitarian network is being hollowed out. It's hard to know what we US Catholics can do in response. Bill hasn't given up hope, though, and he and his team are working hard to figure out how to keep doing their essential, life-saving work around the world. He also shared some practical ways we can all pitch in to help support the mission. Bill O'Keefe: https://www.crs.org/about/leadership/bill-o%E2%80%99keefe Tell Congress to urge the administration to reverse terminations of life-saving aid, disperse funding: https://support.crs.org/act/foreign-aid-operations?ms=mamcrs0225app00fea00 CRS Rice Bowl: https://www.crsricebowl.org/ AMDG is a production of the Jesuit Media Lab, which is a project of the Jesuit Conference of Canada and the United States. www.jesuits.org/ www.beajesuit.org/ twitter.com/jesuitnews facebook.com/Jesuits instagram.com/wearethejesuits youtube.com/societyofjesus www.jesuitmedialab.org/

Jackie Campbell shares her experiences at the CRS (Country Radio Seminar) event in Nashville, where she met iconic country music artists like Duane Allen of The Oak Ridge Boys. The conversation delves into the nostalgia of meeting musical legends, the legacy of The Oak Ridge Boys, and the importance of trust in both personal and professional relationships. Allen reflects on his long career, the significance of trust in business, and the bonds formed through music. For more information or to schedule a consultation call 352-251-1015 or visit www.mycampbellandco.com! Follow us on social media: Facebook | YouTube | X | InstagramSee omnystudio.com/listener for privacy information.

This week, Brandon Bowen discusses the intersection of music, legacy, and financial planning. The conversation begins with insights from the Country Radio Seminar (CRS) and the impact of social media on the music industry. Brandon emphasizes the importance of building a legacy, both in music and personal finance, drawing lessons from artists like Old Dominion and Chip Esten. The episode highlights practical financial advice for listeners looking to secure their legacy through effective retirement planning. Like what you hear? Get a second opinion today: bowenwealth.com Follow us on social media: YouTube | Facebook | LinkedInSee omnystudio.com/listener for privacy information.

We wanna hear from you! Send us a message here :) We're at CRS 25' with Lucas Hoge & Darryl Worley! Find out more about each artist below! With equal ease and finesse, No. 1 Billboard-charting artist Lucas Hoge can craft a song, cast a line, or call in a turkey in front of a film crew - all while holding an audience's attention on stage when performing. As a warm, engaging television host on hit Sportsman Channel, Heartland Network, and American Country Network show Hoge Wild, Hoge finds himself in over 155 million households annually, taking viewers across the globe as he travels to places like New Zealand, Bolivia, South Africa, and unchartered territory in North America. With a guitar in one hand and a bow in the other, Hoge treks the world to amplify his passion for the outdoors and change the narrative around conservation with each weekly Hoge Wild episode. Season 5 began airing in June 2024 and, in the first four months, has already seen over 10 million minutes viewed. Stay connected with Lucas here. The rich, reedy tones and all-American, blue-collar themes in his #1 hits “I Miss My Friend,” “Awful, Beautiful Life” and “Have You Forgotten?” are reminders of the down-to-Earth, Haggard-like Darryl Worley you always knew. The island vibes and blue-eyed soul in new songs “It's Good To Be Me,” “Lay It On Me” and “Lonely Alone” suggest there's another, almost-funky, version of Worley that's been kept under wraps. The alternate sides are both on display in Second Wind: Latest and Greatest, a project that mixes the traditional-country history he established in Nashville with the ragged soul that's deep in the bones of Muscle Shoals, a musical Alabama hotbed where Worley got his start. The area hosted hit sessions for Aretha Franklin, Bob Seger, Wilson Pickett and The Rolling Stones, and the sweaty swagger of the region's recording studios was a perfect fit for Worley as he recorded an album that re-establishes him in country culture. Stay connected with Darryl here. Support the show

Episode Summary In this episode of the Canadian Immigration Podcast, host Mark Holthe and co-host Igor Kyryliuk dive into the latest category-based Express Entry draws and the major changes announced by IRCC. With some occupations removed, new categories introduced, and controversial priorities in focus, Mark and Igor break down what's changed, who benefits, and who is left scrambling for options. With the Provincial Nominee Program (PNP) allocations slashed, IT occupations removed from STEM draws, and French language candidates dominating Express Entry invitations, it's more important than ever to understand where you stand and what your best strategy is moving forward. Key Topics Discussed Breaking Down the Category-Based Draws: What's Changed? The removal of key occupations, including software engineers and truck drivers. New additions: Education occupations and… insurance agents in STEM? The government's shifting immigration priorities—is this about labor shortages or politics? Who Wins, Who Loses? Winners: Francophones, healthcare workers, and some skilled trades. Losers: IT professionals, transport workers, and general skilled workers without category-based eligibility. The huge gap in the job market—are these changes actually solving Canada's labor shortages? French Language Dominance in Express Entry The disproportionate number of draws for French speakers—why is this happening? 74 extra CRS points for French proficiency—is it fair compared to LMIA-based job offers? How this impacts non-French-speaking candidates and Express Entry cut-off scores. Strategic Advice: What You Can Do Next How to pivot if your occupation was removed from the draw list. Exploring alternative programs—should you switch to PNPs, study permits, or job offers? Why leaving Canada could actually be your best path to PR in the future. The importance of tracking Express Entry trends and adapting quickly. Key Takeaways ✅ Express Entry priorities have changed—adapt or risk losing your chance at PR.✅ STEM draws are no longer a safe bet—most IT occupations have been removed.✅ French language remains the biggest Express Entry advantage—74 bonus CRS points.✅ Healthcare and trades still have strong demand, but some workers are left out.✅ Strategic planning is critical—book a consult to explore your best path forward. Quotes from the Episode Mark Holthe:"How did insurance agents and brokers make it into the STEM category while software engineers got removed? Somebody, please explain this to me!" Igor Kyryliuk:"If you think Express Entry is stable and predictable, think again. IRCC can change the game at any time, and you need to be prepared." Links and Resources Watch this episode on YouTube Canadian Immigration Podcast Book a consult Subscribe for MoreStay up-to-date with the latest in Canadian immigration by subscribing to the Canadian Immigration Podcast on iTunes, Spotify, or YouTube. Don't miss future episodes on policy changes, strategies, and practical advice for navigating Canada's immigration process. Disclaimer This episode provides general information about Canadian immigration and is not intended as legal advice. For personalized assistance, consult an immigration lawyer.

Click nsti.com/checkout to receive your $1 jump start at New Saint Thomas Institute for your Catholic Bible in a Year, Catholic Bible Cheat Sheet, and Catholic Lifetime Reading List and 10 Catholic Courses from Dr. Taylor Marshall on Catholic Bible, Catholic Philosophy, Latin Mass, Church Fathers, Mariology and more. https://meetfabric.com/taylor — Help protect your family today with Fabric by Gerber Life. You could be offered coverage instantly with NO health exam required! This hits on the nature of charity as an industry: https://www.lepantoin.org/wp/a-questi… This article is all about the quid-pro-quo relationship that the USCCB and CRS have with USAID: https://www.lepantoin.org/wp/us-bisho… Get Dr. Taylor Marshall's new book on St Nicholas Click Here 2025 Traditional Catholic Calendar Click Here Get a FREE signed copy of the book Rosary in 50 Pages (AND a free Rosary) mailed to you while the offer lasts: patreon.com/drtaylormarshall Dr Taylor Marshall's newest book: Antichrist and Apocalypse – Click Here or get an autographed copy at  patreon.com/drtaylormarshall Dr Marshall's previous book: Infiltration – The Plot to Destroy the Church from Within: Click Here � Real Estate for Life: realestateforlife.org (and select “Dr. Taylor Marshall Show”) Will you please help me in 3 ways? ��� � 1) Please click Thumbs-Up Like Button � if you like it. � 2) Please SHARE � this video on � FACEBOOK/Twitter using the “Share” Button next to Like Button. � 3) Please SUBSCRIBE (and click bell �) to my � CHANNEL: https://www.youtube.com/c/DrTaylorMar… Follow Dr Taylor Marshall on Social Media: � Taylor's YouTube: https://www.youtube.com/c/DrTaylorMar… � Taylors Facebook: / drtaylormarshall � Taylor's Twitter: / TaylorRmarshall Take Dr. Marshall's online Catholic courses by signing up as a student at NSTI: New Saint Thomas Institute Thank you! Please LIKE � and SUBSCRIBE � Learn more about your ad choices. Visit megaphone.fm/adchoices

On episode 2 of the SITREP (Situation Report), Rep. Crenshaw drops the facts – not the Influencer Industrial Complex spin - on the Continuing Resolution that passed the House late Friday evening. He explains what was in the original CR that failed earlier this week and why it was so controversial. And he walks us through the reality of how budgets are negotiated in Congress.   ·      Explanation of what a Continuing Resolution (CR) is ·      The federal budget process: appropriations vs. authorizations ·      Challenges of bipartisan compromise in budget negotiations ·      The role of the Senate in passing appropriations bills ·      The impact of a government shutdown and why CRs are common ·      Details about the latest CR negotiations, including: ·      Pharmacy Benefit Manager Price Transparency Act ·      Disaster aid and farm bill extensions ·      Restrictions on outbound investments to China ·      Expiring healthcare programs, such as traumatic brain injury research and the SUPPORT Act ·      Political misinformation about the CR (e.g., Ukraine aid, congressional pay raises) ·      The argument for and against a debt ceiling ·      The consequences of government shutdowns on families and national finances ·      Internal disagreements within Congress on legislative priorities ·      Explanation of suspension votes and their significance ·      Discussion on splitting legislation into smaller bills for voting ·      Updates on ongoing negotiations and possible outcomes

Watch The X22 Report On Video No videos found Click On Picture To See Larger PictureThe [DS] /[CB] is imploding and the [CB] is trying to keep it from crashing, not because they want the economy to thrive because they war waiting for Trump to take office. Florida looking into gold to counter the fiat currency. The fake news pushing the narrative that Trump's policies will cause the economy to crash. The [DS] is now pushing a multi level plan that consists of riots, plandemic, solar flares, drone warfare and war.  The drones are most likely US based and they are using them for tracking. The [DS] will use this to push fear into the public. Raskin is now demanding Trump use the FBI for background checks. The [DS] is panicking, they are not in control.   (function(w,d,s,i){w.ldAdInit=w.ldAdInit||[];w.ldAdInit.push({slot:13499335648425062,size:[0, 0],id:"ld-7164-1323"});if(!d.getElementById(i)){var j=d.createElement(s),p=d.getElementsByTagName(s)[0];j.async=true;j.src="//cdn2.customads.co/_js/ajs.js";j.id=i;p.parentNode.insertBefore(j,p);}})(window,document,"script","ld-ajs"); Economy https://twitter.com/KobeissiLetter/status/1867589390752522681  vacancies are 5% below pre-pandemic levels. This is in contrast to October US job openings reported by the BLS which have declined 34% since February 2022 and are ~8% above the pre-pandemic. However, data provided by Indeed is more current than the BLS-provided series, which suggests US job openings will continue to fall in the coming months. The labor market is set for more weakness. https://twitter.com/KobeissiLetter/status/1867280198045249637   and significantly above the World War 2 levels. The worst part? Current projections assume lower interest rates and no recessions over the next decade. In Q3 2024, annualized net interest costs reached a record $1.12 trillion. What happens if a recession hits? https://twitter.com/DOGE/status/1867347161886994485   New report: Taxpayers subsidize swanky country club memberships for World Bank and International Monetary Fund staffers in D.C. According to an exclusive report from the New York Post yesterday, Staffers at the International Monetary Fund and the World Bank raking in six-figure, tax-free salaries at both global bodies qualify for free memberships at the Bretton Woods Recreation Center in Maryland, according to documents obtained by The Post.   Stiff initiation fees at the IMF-owned course — which range from $12,000 to $20,000 — are automatically waived for all employees on the payroll of the two institutions, according to the documents, which are not in the public domain. Now, how are those membership fees effectively subsidized? Well, the U.S. taxpayer has “financial commitments” to the World Bank and the IMF numbering into the hundreds of billions, and American tax dollars (and debt) remain the top “contributor” to both institutions. Here's this, from a Congressional Research Service report released in May of this year:   And, from a CRS report released in 2022 on the IMF's financial structure: The United States contributes $117 billion to the IMF quota (17.46%). In addition, the United States has contributed $44 billion to funds at the IMF that supplement quota resources.   Source: americanthinker.com   https://twitter.com/KobeissiLetter/status/1867361922255139235    markets. They shouldn't be looking for every last penny knowing how many families are hurt. They've got record profits, and I'd rather these foreign companies spend it on the great men and women on our docks, than machinery, which is expensive, and which will constantly have to be replaced. In the end, there's no gain for them, and I hope that they will understand how important an issue this is for me. For the great privilege of accessing our markets, these foreign companies should hire our incredible American Workers, instead of laying them off,